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We are developing an orally available small-molecule, allosteric TSH receptor (TSHR) 
agonist for follow-up diagnostics of patients with thyroid cancer. The agonist C2 
(NCGC00161870) that we have studied so far is a racemic mixture containing equal 
amounts of two enantiomers, E1 and E2. As enantiomers of many drugs exhibit different 
pharmacologic properties, we assessed the properties of E1 and E2. We separated the 
two enantiomers by chiral chromatography and determined E2 as the (S)-(+) isomer via 
crystal structure analysis. E1 and E2 were shown to bind differently to a homology model 
of the transmembrane domain of TSHR in which E2 was calculated to exhibit lower bind-
ing energy than E1 and was, therefore, predicted to be more potent than E1. In HEK293 
cells expressing human TSHRs, C2, E1, and E2 were equally efficacious in stimulating 
cAMP production, but their potencies were different. E2 was more potent (EC50 = 18 nM) 
than C2 (EC50 = 46 nM), which was more potent than E1 (EC50 = 217 nM). In primary 
cultures of human thyrocytes, C2, E1, and E2 stimulated increases in thyroperoxidase 
mRNA of 92-, 55-, and 137-fold and in sodium–iodide symporter mRNA of 20-, 4-, 
and 121-fold above basal levels, respectively. In mice, C2 stimulated an increase in 
radioactive iodine uptake of 1.5-fold and E2 of 2.8-fold above basal level, whereas E1 
did not have an effect. C2 stimulated an increase in serum T4 of 2.4-fold, E1 of 1.9-fold, 
and E2 of 5.6-fold above basal levels, and a 5-day oral dosing regimen of E2 increased 
serum T4 levels comparable to recombinant human TSH (rhTSH, Thyrogen®). Thus, E2 
is more effective than either C2 or E1 in stimulating thyroid function and as efficacious as 
rhTSH in vivo. E2 represents the next step toward developing an oral drug for patients 
with thyroid cancer.
Keywords: Tsh receptor, agonist, allosteric, enantiomer, racemic
inTrODUcTiOn
Recombinant human TSH (rhTSH, Thyrogen®), by activating the TSH receptor (TSHR), has been 
used to great advantage in the initial treatment and follow-up of patients with thyroid cancer, and to 
a more limited extent as an adjunct in the treatment of patients with nodular goiter (1–4). rhTSH is 
administered via intramuscular injection over two consecutive days prior to radioactive iodine uptake 
(RAIU) and/or thyroglobulin (TG) testing. We have been interested in developing small-molecule 
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ligands for the TSHR (5), which is a G protein-coupled (or 
seven transmembrane-spanning) receptor (GPCR) (6), and have 
reported on a “drug-like” TSHR agonist C2 (NCGC00161870) 
that was identified by high-throughput screening and subsequent 
chemical modification of the hit compound (7). We suggest that 
C2 could be used in patients in place of rhTSH. Small-molecule 
ligands are generally much more easily employed as drugs com-
pared to peptides or proteins. They are synthesized chemically, 
can be produced in large quantities, and can typically be given 
orally as they are generally stable within and can be absorbed 
through the gastrointestinal tract. Therefore, a small-molecule 
TSHR agonist would offer benefits over the current standard of 
care to both clinicians and patients by providing a non-invasive 
route of drug administration at reduced economic costs as a result 
of patients being able to self-administer an oral bio-equivalent 
drug rather than requiring the need of a trained clinical profes-
sional to administer intramuscular injections of rhTSH.
C2 is a low-molecular-weight (524  Da) organic compound 
and was shown to bind within the transmembrane-spanning 
domain of TSHR and is termed an allosteric ligand since the 
cognate ligand TSH binds to the extracellular domain of the 
receptor (7). In an in vitro system of human thyrocytes in pri-
mary culture, C2, like TSH, induced upregulation of mRNAs 
for TG, thyroperoxidase (TPO), sodium–iodide symporter 
(NIS) and type II iodothyronine deiodinase (DIO2). In vivo, 
C2 increased serum thyroxine (T4) and thyroidal radioiodine 
uptake in mice (7).
C2 contains a chiral center and the racemic mixture contains 
two enantiomers, E1 and E2. Our studies until the present were 
performed with the racemic mixture containing equal amounts 
of the two enantiomers.
Enantiomers are two stereoisomers that are mirror images 
of each other and are not superimposable. The different 
enantiomers of a number of drugs have been shown to exhibit 
marked differences in biological activities, such as pharmaco-
dynamic and pharmacokinetic properties, metabolism, and 
toxicology (8–10). Of particular note is that specific differences 
in affinity for binding to GPCRs have been found for drug 
enantiomers (11–13). In 1992, the United States Food and Drug 
Administration (FDA) issued guidelines and policies with regard 
to compounds that have stereochemistry (http://www.fda.gov/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
ucm122883.htm). These guidelines suggest considering stereo-
chemistry as early as possible in the search for new drug candi-
dates, and analysis and characterization of enantiomers of a drug 
in early animal testing and in clinical trials. Single enantiomers 
have a more selective pharmacodynamics profile as compared 
to the racemic mixture and have lesser adverse drug reactions. 
Therefore, separation of enantiomers may allow for safer and 
more effective drugs, and may lead to drugs with improved 
therapeutic activity (14, 15).
Herein, we report the separation of the two enantiomers of C2 
by chiral chromatography and evaluate differences in their bio-
logical effects using in vitro and in vivo systems. Our data reveal 
E2 is the (S)-(+) enantiomer, which is more effective than either 
C2 or the E1 enantiomer in stimulating thyroid function and 
fundamentally equivalent to rhTSH in our in vivo mouse model.
MaTerials anD MeThODs
chiral separation of c2
C2 was synthesized as described previously (7). The enantiomers 
E1 and E2 in the racemic C2 mixture were separated by chiral 
chromatography using a Chiralpak IA column on a Shimadzu 
LC-20AT instrument (performed by Pharmaron® Beijing 
Company, Ltd, China). The retention times of E1 and E2 were 
3.64 and 4.51 min, respectively.
crystal structure Determination 
of enantiomer e2
The single-crystal X-ray diffraction studies were performed by 
Dr. Curtis Moore at the University of California, Crystallography 
Laboratory, San Diego, CA, USA. They were carried out on a 
Bruker Kappa APEX-II CCD diffractometer equipped with Cu 
Kα radiation (λ = 1.5478). Crystals of the subject compound were 
grown by vapor diffusion of pentane into a dichloroethane solu-
tion. A 0.153 mm × 0.055 mm × 0.031 mm colorless needle was 
mounted on a Cryoloop with Paratone oil. Data were collected in 
a nitrogen gas stream at 100(2) K using φ and ω scans. Crystal-
to-detector distance was 45  mm using variable exposure time 
(5–30 s) depending on θ with a scan width of 1.0°. Data collection 
was 99.5% complete to 68.00° in θ. A total of 32,360 reflections 
were collected covering the indices −11 ⇐ h ⇐ 11, −13 ⇐ k ⇐ 12, 
−27 ⇐ l ⇐ 27. A total of 13,810 reflections were found to be sym-
metry independent, with a Rint of 0.0278. Indexing and unit cell 
refinement indicated a primitive, triclinic lattice. The space group 
was found to be P1. The data were integrated using the Bruker 
SAINT Software program (Bruker AXS Inc., Madison, WI, USA) 
and scaled using the SADABS Software program. Solution by 
direct methods (SHELXT) (16) produced a complete phasing 
model consistent with the proposed structure. All non-hydrogen 
atoms were refined anisotropically by full-matrix least-squares 
(SHELXL-2014). All hydrogen atoms were placed using a riding 
model. Their positions were constrained relative to their parent 
atom using the appropriate HFIX command in SHELXL-2014. 
Crystallographic data are available upon request.
Molecular Modeling of Tshr
A homology model was generated of the transmembrane region 
of TSHR. A BLAST (Basic Local Alignment Search Tool) search 
(17) was conducted to find a template receptor with a solved 
structure that had high sequence identity to TSHR. Due to high 
sequence identity and hypothesized similarities between active 
conformations of both receptors, the crystallographic structure 
of active bovine rhodopsin (PDB: 2X72) at 2.8Å resolution was 
ultimately chosen. The alignment between the sequences of these 
receptors was initially achieved using ClustalX version 2.1 (18), 
with refinement conducted manually for the looped regions.
The model of TSHR was determined through the combined 
information contained within the alignment and the crystal-
lographic structure of the template receptor using the library 
MODELLER version 9.15 (19, 20). Based on these initial condi-
tions, 50 potential models were generated and ranked by objective 
scoring functions (DOPE, GA341). A final model was selected 
based on favorable scores and conserved geometry determined 
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by PROCHECK (21). Molecular dynamics (MD) simulations 
were used to refine the model of TSHR by modeling the receptor 
in a similar setting to that of the receptor in vivo. The receptor 
was embedded into a 1,2-dilauroylphosphatidic acid lipid bilayer 
and solvated by water and potassium or chloride ions. The final 
MD simulation was carried out using the GROMACS version 
5.0 MD package (22). The calculations were performed with 
the CHARMM (Chemistry at Harvard Molecular Mechanics) 
force field (23) for 100 ns at 310°K. The simulation was run on 
Biowulf2, a massively parallelized high performance cluster at 
the National Institutes of Health (NIH). A representative model 
was chosen from these simulations for docking studies. Autodock 
Vina (24) was used to dock E1 and E2.
Measurement of caMP Production
HEK293 cells stably expressing TSHR (HEK-TSHR), luteinizing 
hormone receptor (LHR) (HEK-LHR), or follicle-stimulating 
hormone receptor (FSHR) (HEK-FSHR) were described previ-
ously (25). Cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, 
100  units/ml penicillin and 10  μg/ml streptomycin (Life 
Technologies Corporation, Carlsbad, CA, USA) at 37°C in a 
humidified 5% CO2 incubator. Twenty-four hours before the 
experiment, 1.1  ×  105  cells/ml were seeded in 48-well plates. 
Subsequently, growth medium was replaced by HBSS/10  mM 
HEPES containing 1 mM 3-isobutyl-1-methylxanthine (IBMX) 
(Sigma-Aldrich, St. Louis, MO, USA) and cells were incubated 
with small-molecule ligands C2, E1, or E2 in a humidified 5% CO2 
incubator at 37oC for 1 h. Following aspiration of the medium, 
cells were lysed using lysis buffer of the cAMP-Screen DirectTM 
System (Life Technologies Corporation). The cAMP content of 
the cell lysate was determined using the method described in 
the manufacturer’s protocol. The potencies (i.e. EC50s) of the 
compounds were obtained from the dose–response curves using 
GraphPad Prism Version 5 for Windows (GraphPad Software, La 
Jolla, CA, USA).
Primary cultures of human Thyrocytes
Human thyrocytes were isolated from normal thyroid tissue sam-
ples from patients undergoing thyroidectomy for thyroid cancer 
at the National Institutes of Health Clinical Center. Specimens 
were obtained under National Institute of Diabetes and Digestive 
and Kidney Diseases (NIDDK) Institutional Review Board 
approved protocols after informed consent was obtained from 
patients. Cultures of primary thyrocytes were established as 
described previously (7).
Measurement of sodium–iodide 
symporter and Thyroperoxidase 
expression in Primary cultures of human 
Thyrocytes
Thyrocytes (0.5 × 105 cells/well) were seeded into 24-well plates 
in DMEM containing 10% FBS. Twenty-four hours prior to the 
experiment, media were changed to 0.1% bovine serum albumin 
(BSA)-containing DMEM. Cells were stimulated with C2, E1, or 
E2 for the indicated times.
Total RNA was purified using RNeasy Mini Kits (Qiagen 
Inc., Valencia, CA, USA). First-strand cDNA was prepared 
using a High Capacity cDNA Reverse Transcription Kit (Life 
Technologies Corporation). RT-PCR was performed in 25  μl 
reactions using cDNA prepared from 100 ng or less of total RNA 
and TaqMan Universal PCR Master Mix (Life Technologies 
Corporation). Levels of mRNA were measured using primers 
and probes from Life Technologies Corporation. Quantitative 
RT-PCR results were normalized to GAPDH to correct for dif-
ferences in RNA input.
Measurement of serum Total T4 in Mice
All animals were maintained at NIH facilities in accordance with 
the guidelines established by the Association for Assessment 
and Accreditation of Laboratory Animal Care (AALAC) and all 
protocols were approved by the Institutional Animal Care and 
Use Committee at the NIDDK. Mice were housed up to five per 
cage and maintained on a 12:12  h light–dark cycle with lights 
out at 06:00 p.m. The animal room was maintained at 22°C and 
50% humidity. Mice were maintained on standard rodent chow 
(NIH-31; Zeigler Brothers, Inc., Gardners, PA, USA). Water and 
feed were available ad libitum. At the time of experiments, mouse 
ages ranged from 8 to 13 weeks.
Comparison of C2, E1, and E2 regarding the 
Increase of Serum Total T4
Experiments to compare the racemic mixture C2 with the 
enantiomers E1 and E2 were carried out in female BALB/c 
mice (National Cancer Institute Animal Production Program, 
Fredrick, MD, USA). Compounds were dissolved in a vehi-
cle consisting of 100% polyethylene glycol 300 (PEG 300) 
(Hampton Research, Aliso Viejo, CA, USA). 3,3′,5-Triiodo-l-
thyronine sodium (T3, Sigma-Aldrich) was dissolved in 0.1 N 
sodium hydroxide (NaOH) (Sigma-Aldrich). T3 was further 
diluted to a concentration of 50 μg/ml with phosphate buffered 
saline (PBS).
The treatment groups were vehicle, C2, E1, and E2 at 0.5 or 
1 mg per animal. Animals were dosed via intraperitoneal injec-
tion. T3 (5 μg/animal) was given intraperitoneally in the morning 
of each treatment day to inhibit endogenous TSH secretion. C2, 
E1, or E2 were given once or twice daily. Serum was obtained by 
terminal retro-orbital bleed from anesthetized mice 4 h after the 
last injection.
Optimization of E2 Dosing Schedule, and 
Comparison of E2 and rhTSH regarding 
the Increase of Serum Total T4
Experiments to optimize the dosing schedule of E2, and to 
compare E2 to rhTSH were performed in female CD1 mice 
(Charles River Laboratories, Bar Harbor, ME, USA). E2 and T3 
were dissolved as described above. T3 was further diluted to a 
concentration of 3 μg/ml with distilled water (T3 water). rhTSH 
(Thyrogen®) was purchased from Sanofi Genzyme, Cambridge, 
MA, USA. The drinking water was replaced with T3 water 6 days 
prior to treatment to inhibit endogenous TSH secretion. Two 
milligram E2 per animal was administered orally once or twice 
a day for two or five consecutive days. Four microgram rhTSH 
FigUre 1 | (a) Two-dimensional structures of the racemic mixture C2 and of 
the enantiomers E1 and E2. (B) Crystal structure of the (S)-(+)-enantiomer E2.
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per animal (a converted human equivalent dose) was given 
intraperitoneally once a day on two consecutive days. Serum 
was obtained by terminal retro-orbital bleed from anesthetized 
mice 2 h after the last injection. Total T4 levels were measured 
with the GammaCoatTM T4 Radioimmunoassay (DiaSorin Inc., 
Stillwater, MN, USA) using the manufacturer’s protocol.
Thyroidal radioiodine Uptake in Mice
Experiments were performed with female CD1 mice. At the 
time of experiments, mouse ages ranged from 8 to 10 weeks. C2, 
E1, and E2 were dissolved in a vehicle consisting of 10% N,N-
dimethylacetamide (Sigma Aldrich) and 90% PEG 300 (Hampton 
Research). Na125I (Perkin-Elmer, Waltham, MA, USA) with a 
specific activity of 17 Ci/mg in 0.1 N NaOH was diluted in PBS 
to provide an activity of 100 μCi/ml.
To measure iodine uptake, animals were assigned to one of 
four treatment groups based on body weight. Their drinking water 
was replaced with T3 water 6 days prior to treatment to inhibit 
endogenous TSH secretion. They were subsequently maintained 
on the T3 water until the conclusion of the experiment. The 
treatment groups were Control (vehicle), C2, E1, and E2 at 2 or 
10 mg per animal. Animals were dosed via oral gavage with either 
vehicle or test compound once a day for 2 days. One the third 
day, they were injected intraperitoneally with 200 μl (20 μCi) of 
125I. Twenty-four hours later their thyroid glands and livers (as a 
control) were excised and counted in a gamma counter (Perkin 
Elmer Model 1470, Perkin Elmer). Iodine uptake was measured 
as the number of counts per minute.
statistical analysis
Statistical analysis was performed by GraphPad Prism  version 
5 for Windows. Data are presented as mean  ±  SE values. 
Statistically significant differences among groups were assessed 
by t-test.
resUlTs anD DiscUssiOn
Figure  1 illustrates the 2D structures of the racemic mixture 
C2, the enantiomers E1 and E2 (A), and the crystal structure of 
E2 (B). The crystal structure of E2 shows it to be the (S)-(+)-
enantiomer. Figure 2 shows comparisons of the docking of E1 
and E2 to the serpentine transmembrane domain of the homol-
ogy model of TSHR. We demonstrated previously (7) that the 
racemic mixture C2 binds in this region with specific interactions 
with an asparagine residue (N590) in transmembrane helix 5 
[N5.47 in the Ballesteros and Weinstein nomenclature (26)]. 
This new TSHR model confirms the previous binding pocket 
and shows important differences in the binding of E1 and E2. 
The resulting conformations of both enantiomers were situated 
in the transmembrane domain of TSHR. However, the binding 
energy of E2 was significantly more favorable (−9.2  kcal/mol) 
than that of E1 (−5.6 kcal/mol). Upon further evaluation of the 
interactions between each enantiomer and the receptor, E2 had 
several potential hydrogen bonding and π–π interactions with 
key amino acid residues [T501 (T3.32), V502 (V3.33), S505 
(S3.36), E506 (3.37), F585 (F5.42), S641 (S6.52), K660 (K7.35), 
Y667 (Y7.42)], while E1 generally had weaker lipophilic and 
hydrophilic interactions, along with just two π–π interactions. 
Thus, E2 is predicted to be a more potent TSHR agonist than E1 
based on the enantiomer binding model.
Figure  3 illustrates a comparison of the dose-dependent 
stimulation of cAMP production in HEK-TSHR cells. We use 
these engineered cells because they exhibit a robust cAMP signal 
and allow differences in potencies of different agonists to be 
quantified. Like C2 (7), E1 and E2 stimulated cAMP production 
in cells expressing TSHRs but not in cells expressing LHRs or 
FSHRs, which have high homology to TSHR in the transmem-
brane domain (data not shown). Thus, E1 and E2 are specific 
agonists for TSHR. C2, E1, and E2 exhibited similar maximal 
increases in cAMP production but different potencies. E2 was 
more potent (EC50 = 18 nM) than C2 (EC50 = 46 nM), which was 
more potent than E1 (EC50 = 217 nM). These findings supported 
the predictions from the homology models and predicted that E2 
would be more active than C2 and E1 in other assays of thyroid 
cell function.
It was important to confirm this hierarchy in signaling in 
a more physiologically relevant system with endogenously 
expressed TSHRs. We used primary cultures of human thyro-
cytes and measured the effects of all three TSHR agonists on 
upregulation of thyroid-specific mRNA levels of NIS and TPO. 
Thyroidal iodide influx, iodide efflux, and iodide organification 
are mediated by NIS (27–29) and determine radioactive iodine 
accumulation. TSH is the main regulator of NIS transcription in 
FigUre 3 | e2 is more potent than c2 that is more potent than e1 in 
stimulating caMP production in heK-Tshr cells. Cells were stimulated 
by increasing doses (0–30 μM) of C2, E1, or E2 as described in Section 
“Materials and Methods.” The intracellular cAMP levels were measured after 
1 h incubation with the small-molecule ligands by ELISA. The data are from 
three experiments with duplicate samples and are presented as mean ± SE.
FigUre 2 | comparison of the poses and spatial locations of e1 (magenta) and e2 (green) in the homology model of Tshr. Both compounds docked 
into the allosteric binding site within the transmembrane serpentine domain of TSHR. The E1/E2 overlay shows that the orientations and TSHR interacting amino 
acid residues are different for E1 and E2.
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normal thyroid cells (30) and increases NIS mRNA and protein 
levels (31, 32). TPO plays a key role in thyroid hormone synthesis 
by catalyzing both the iodination of tyrosine residues and the 
coupling of iodotyrosine residues in TG, resulting in the forma-
tion of T3 and T4 (33). Figure 4 illustrates the effects of C2, E1, 
and E2 on upregulation of TPO and NIS gene expression. A time 
course over 8 days showed a maximum increase in NIS and TPO 
gene expression on day 5 (data not shown). In cells stimulated 
by 10 μM doses of each compound for 5 days, C2 stimulated an 
increase in thyroidal NIS mRNA of 20 ± 2.5-fold, E1 of 3.6 ± 0.6-
fold, and E2 of 121 ± 6.4-fold above basal levels. Similarly, TPO 
mRNA increased over basal 92 ±  13-fold for C2, 55 ±  9-fold 
for E1, and 137 ±  21-fold for E2. Thus, E2 was more effective 
in upregulating NIS and TPO gene expression than either C2 or 
the E1 enantiomer. These findings in primary cultures of human 
thyrocytes are consistent with those found in the engineered 
HEK-TSHR cells (Figure 3).
Most importantly, we determined whether there were 
differences between the enantiomers in stimulating biologic 
responses in mice. Figure  5 shows the effects of C2, E1, and 
E2 on two measurements of thyroid function: (i) T4 secretion 
in serum, and (ii) RAIU. For T4 levels, the same hierarchy was 
found – E2 > C2 > E1 – as was revealed in the in vitro studies. 
Figure 5A summarizes the results of three independent experi-
ments. In mice administered 0.5  mg (experiments 1 and 2) or 
1 mg (experiment 3) of each compound intraperitoneally twice a 
day, C2 stimulated an increase in serum T4 of 2.4 ± 0.3-fold, E1 
of 1.9 ± 0.2-fold, and E2 of 5.7 ± 0.4-fold above basal levels. The 
data of each individual experiment are presented in Figure S1 in 
Supplementary Material.
Radioactive iodine thyroid scans are commonly used to 
diagnose residual and/or recurrent thyroid cancer. For the last 
decade, rhTSH has been used in the follow-up of thyroidectomy 
to increase the sensitivity for detection of recurrent or metastatic 
thyroid cancer in patients who undergo regular monitoring (2). 
In addition, rhTSH was approved by the FDA for a supplemental 
indication to improve radioiodine ablation of thyroid remnants 
after surgical thyroidectomy in patients with thyroid cancer (34). 
A small-molecule TSHR agonist could replace rhTSH because it 
could produce the same beneficial effects but with greater ease of 
oral administration and, therefore, would be available for use in a 
larger patient population. Figure 5B represents a summary of two 
independent RAIU experiments with five animals per condition 
in each experiment (total n =  10). The RAIU in mice showed 
the same order of enantiomer activity as observed in the serum 
T4 assay. E1 did not increase RAIU whereas E2 was significantly 
more effective than C2. Two or 10 mg of each agonist were given 
orally once daily on two consecutive days in the first and second 
experiment, respectively. C2 stimulated an increase in RAIU of 
1.5 ± 0.1-fold, and E2 of 2.8 ± 0.4-fold above basal levels.
In clinical practice, rhTSH is administered intramuscularly on 
two consecutive days. Our in  vitro data in primary cultures of 
FigUre 4 | e2 was more effective than c2 that was more effective than e1 in upregulating the gene expression of TPO (a) and nis (B) in primary 
cultures of human thyrocytes. Cells were stimulated with 10 μM C2, E1, or E2 for 5 days. mRNA levels were measured by quantitative RT-PCR. The data 
represent the mean ± SE in two experiments with duplicate samples. Data were analyzed by t-test; TPO: **p < 0.01, C2, E1, and E2 versus Control; *p < 0.1, E2 
versus C2; NIS: ***p < 0.001, E2 versus Control, and E2 versus C2; **p < 0.01, C2 versus Control; *p < 0.1, E1 versus Control.
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human thyrocytes demonstrated that upregulation of NIS gene 
expression by E2 reached a maximum on day 5. Therefore, we 
optimized our dosing schedule and frequency to maximize the 
E2 response in  vivo. We measured serum T4 levels to further 
evaluate E2 efficacy in  vivo since it was the primary readout 
used to validate the pre-clinical efficacy of rhTSH within its 
Investigational New Drug (IND) application for the FDA. Mice 
were given free access to T3 water for 6 days before the treatment 
FigUre 5 | stimulation of T4 secretion and thyroidal radioiodine uptake in mice by c2, e1, and e2. (a) Serum total T4 was measured in three independent 
experiments. The sum of all data is presented as mean ± SE. The individual experiments are shown in Figure S1 in Supplementary Material. The experiments had 
four to six mice per treatment group. T3 (5 μg/mouse) was given intraperitoneally in the morning of each treatment day to inhibit endogenous TSH secretion. 
Animals were dosed with TSHR ligands via intraperitoneal injection. Experiment 1: 0.5 mg of each compound was given in the afternoon of day 1, in the morning 
and afternoon of day 2, and in the morning of day 3. Experiments 2 and 3: 0.5 or 1 mg of each compound, respectively, was given twice a day on days 1 and 2, 
and one morning dose was given on day 3. Serum was obtained by terminal retro-orbital bleed from anesthetized mice 4 h after the last injection. Data were 
analyzed by t-test; ****p < 0.0001, C2, and E2 versus Control, E2 versus C2; ***p < 0.001, E1 versus Control. There is no significant difference between C2 and E1. 
(B) Radioiodide uptake: animals were dosed via oral gavage with either vehicle or test compound (2 mg in experiment 1 and 10 mg in experiment 2) once a day for 
2 days. Each experiment had five mice per treatment group (total n = 10). On the third day, mice were injected intraperitoneally with Na125I. Twenty-four hours later, 
radioiodine uptake was measured. The results of two experiments were combined and are presented as mean ± SE. The data were analyzed by t-test; 
***p < 0.001, E2 versus Control; **p < 0.01, C2 versus Control, and E2 versus C2. There is no significant difference between Control and E1.
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